Can Diffusion-Weighted Imaging Detect Antihormonal Resistance in Patients with Prostate Cancer Bone Metastases?
Carolin Reischauer 1,2 , Johannes M. Froehlich 1 , Dow-Mu Koh 3 , Ren Patzwahl 4 , Christoph A. Binkert 4 , Sebastian Kos 1 , and Andreas Gutzeit 1,5
Institute of Radiology and Nuclear Medicine,
Clinical Research Unit, Hirslanden Klinik St. Anna,
for Biomedical Engineering, ETH and University Zurich,
of Radiology, Royal Marsden Hospital, Sutton, United
of Radiology, Cantonal Hospital Winterthur, Winterthur,
of Radiology, Paracelsus Medical University, Salzburg,
Patients suffering from prostate cancer-related bone
metastases initially respond well to antihormonal
treatment. However, after a period of 2-3 years
resistance is usually observed. The present work
investigates whether diffusion-weighted imaging permits
monitoring this process. It has been previously shown
that increased apparent diffusion coefficients (ADCs)
are observed at 1 month after commencement of therapy in
responders to androgen deprivation. Using ADCs and
functional diffusion maps, the present work shows that
this initial increase is followed by decreasing ADCs
with onset of antihormonal resistance.
This abstract and the presentation materials are available to members only;
a login is required.